Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more..
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more.
Chris Gibson, Recursion co-founder and CEO, joins 'Squawk Box' to discuss the company's $688 million acquisition of Exscientia, the use of AI in drug discovery, and more..